Mereo BioPharma — Third Quarter 2026 Earnings Summary

Mereo BioPharma reported a net loss of $5.9 million for the third quarter of 2026, a decrease from $7.0 million in the same period the previous year, driven by reduced research and development and general and administrative expenses. The company held $26.1 million in cash and cash equivalents as of September 30, 2026, which is expected to fund operations into late 2027. Regulatory discussions with Ultragenyx regarding setrusumab for osteogenesis imperfecta continue to determine the necessary data for a potential filing, while collaborations with Sentynl Therapeutics aim to refine the Phase 3 trial design for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease. Additionally, partner āshibio is advancing vantictumab for autosomal dominant osteopetrosis type 2, with clinical trials in patients anticipated to begin in the first half of 2028.